Nitric oxide - ProStrakan

Drug Profile

Nitric oxide - ProStrakan

Alternative Names: S-291-N; TNO therapy - ProStrakan; Topical nitric oxide - ProStrakan

Latest Information Update: 26 Mar 2010

Price : $50

At a glance

  • Originator ProStrakan
  • Class Antiacnes; Antiandrogens; Antibacterials; Antihypertensives; Antivirals; Free radicals; Nitrogen oxides; Non-opioid analgesics; Small molecules; Vasodilators
  • Mechanism of Action Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Human papillomavirus infections; Molluscum contagiosum; Onychomycosis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 08 Sep 2005 This compound is still in active development for Onychomycosis
  • 22 Sep 2004 ProSkelia has merged with Strakan to form ProStrakan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top